据SEC文件显示,Telomir Pharmaceuticals计划将研究范围扩展至胰腺癌和白血病模型,并将进行更多动物实验,为提交新药研究申请(IND)做准备。
据SEC文件显示,Telomir Pharmaceuticals计划将研究范围扩展至胰腺癌和白血病模型,并将进行更多动物实验,为提交新药研究申请(IND)做准备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.